Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01837251
Recruitment Status : Completed
First Posted : April 23, 2013
Last Update Posted : July 13, 2021
Arbeitsgemeinschaft Gynaekologische Onkologie Austria
Australia New Zealand Gynaecological Oncology Group
Scottish Gynaecological Cancer Study Group
Information provided by (Responsible Party):
AGO Research GmbH